Annual Evaluation and Performance Measurement Report (I.2- EXPANDED DRUG SUSCEPTIBILITY TESTING (ExAST) IN JURISDICTION)

Annually, each funded laboratory is required to report to CDC evaluation and performance measures. Data are used to indicate progress made toward program outcomes. These summary reports have to be uploaded to the ELC CAMP at the end of each funding year. Required performance measures are listed below.

|  |
| --- |
| 1. **For metallo beta-lactamase (MBL)-producing CRE isolates requiring testing against aztreonamavibactam drugs (within 3 days of isolate receipt at the public health laboratory):**

a. Numerator: number of isolates tested for ExAST with results reported back to submitter within 3 days of receiving isolateb. Denominator: total number of isolates tested for ExASTc. Calculated: percent of isolates tested for expanded drug susceptibility (ExAST) with results returned to submitter within 3 days of receiving isolate |
| Candida Antifungal Susceptibility Testing (AFST):1. **Total number of Candida isolates tested for Antifungal Susceptibility**
 |
| 1. **Proportion of resistant isolates by species and drug class as indicated according to guidance:**
2. Numerator: number of resistant Candida isolates per species according to guidance
3. Denominator: total Candida isolates tested per species according to guidance
4. Calculated: percent of resistant Candida isolates per species
 |
| **4. Median number and range from Candida isolate availability at public health laboratory (from isolate submission or culture of a swab) to communication of test result** a. Median (in days)b. Range (in days) |